Deadline: March 1, 2013 (Letters of Intent)
The Leukemia & Lymphoma Society has issued new Requests for Proposals through its Translational Research Program to support researchers in six critical areas of unmet medical need. The RFPs mark LLS’s aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs.
The LLS Translational Research Program is designed to help accelerate the movement of promising discoveries from lab to clinic. The goal of translational research is to reduce the time between laboratory findings and actual treatment.
The society aims to stimulate more academic research in the following areas: new immunotherapeutics for patients with acute myelogenous leukemia; novel therapeutics for patients with non-cutaneous T-cell malignancies; introduction of novel agents in the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma; therapies for patients with myelodysplastic syndromes who have failed hypomethylating agents; therapies for new targets such as bromodomains, methylation, and other epigenetic approaches for patients with high-risk myeloma; and research that addresses long-term and late effects of blood cancer therapies.
Applicants (principal investigators) must hold an M.D., Ph.D., or equivalent degree, and work in a nonprofit organization (domestic or foreign), university, college, hospital, or lab. Applications may involve multiple institutions and the applicant should have an independent research or academic position. Applicants need not be United States citizens. Each grant provide up to $600,000 over three years.
Visit the LLS Web site for complete program guidelines and application procedures.
Link to Complete RFP